目的：探讨利妥昔单抗对弥漫大B细胞淋巴瘤患者Th17细胞及相关细胞因子体外的影响及其意义。方法：DLBCL初治患者和体检健康者各20例，每个对象分别采集4份外周血标本，分离外周血单个核细胞(PBMCs)，按照培养条件的不同分成4个亚组：空白组(A亚组)、加入利妥昔单抗组(B亚组)、加入利妥昔单抗和血清组(C亚组)和极化组(D亚组)(加IL-6和TGF-β)。
背景和目的：多发性骨髓瘤患者RANKL表达异常增高使RANKL/RANK信号系统过度激活,导致破骨细胞(Osteoclast,oC)大量生成且功能亢进在骨髓瘤骨病(Myeloma bone disease,MBD)的发生、发展中起关键作用,因此抑制RANKL/RANK信号转导途径从而抑制OC的形成及其破骨功能是治疗MBD有效方法之一。前期研究发现RANK蛋白上存在一个新基序：IVVY,介导了一条O
背景反复输血或使用红细胞生成刺激剂(ESA)都可以用于治疗肾性贫血.但是对两种治疗方法的选择,应该针对患者的实际情况,根据两种治疗方法的相对利弊进行选择.单纯的Hb降低不作为输血的理由,不能为了Hb达标而输血.慢性贫血患者输血是为了防止组织缺氧或心力衰竭.在ESA治疗Hb达标的患者,仅在急性失血(如急性出血、急性溶血、严重炎症或外科血液丢失)时输血.输血患者患急性冠脉综合征时有更高的死亡率.使用输
Background.Recent clinical trials in cancer patients treated with erythropoiesis-stimulating agents (ESAs) and in CKD patients treated to haemoglobin (Hb) targets above the labeled range of 10-12 g/dL
Background and Objectives: Instability of hemoglobin levels during epoetin therapy is a new problem in hemodialysis.We evaluated extent and correlates of time in target, that is, the time spent with h
Background: Anaemia is a known risk factor for cardiovascular disease and treating anaemia in chronic kidney disease (CKD) may improve outcomes.However, little is known about the scope to improve prim
Objective-To determine whether recombinant human erythropoietin improves the quality of fife and exercise capacity of anaemic patients receiving haemodialysis.Design-A double blind, randomised, placeb
Haemoglobin (Hgb) levels are known to be associated with numerous adverse outcomes in both chronic kidney disease (CKD) and non-CKD patients.This analysis evaluates the association of baseline haemogl
Anemia associated with chronic renal insufficiency (CRI) may have substantial clinical and public health importance, butlittle is known about its epidemiology.This study aims to quantify the relations
Hemoglobin levels vary substantially over time in hemodialysis patients, and this variability may portend poor.outcomes.For a given patient, hemoglobin concentration over time can be described by abso